News

pharmaphorum2d
Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma
A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a ...
ascopubs.org5d
IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: A phase I dose-escalation study.
Dose escalation of KY-0118, PD-1, and IL-2v due-target fusion protein in patients with advanced renal clear cell carcinoma, urothelial carcinoma, and malignant melanoma. This is an ASCO Meeting ...
ascopubs.org2d
Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical ...
This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full text component.
pharmaphorum2d
GSK’s twice-yearly asthma drug clears two phase 3 trials
GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company ...
C&EN6d
Simultaneous Fluorescence Visualization of Endoplasmic Reticulum Superoxide Anion and Polarity in Myocardial Cells and Tissue
Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Key Laboratory of Molecular and Nano Probes, Ministry of Education, College of Chemistry, ...
C&EN3d
Polarity and Spin–Orbit Coupling Induced Strong Interfacial Exchange Coupling: An Asymmetric Charge Transfer in Iridate–Manganite Heterostructure
Department of Physics, Southern University of Science and Technology, Shenzhen 518055, China Key Laboratory of Artificial Micro- and Nano-structures of Ministry of Education and School of Physics and ...